| J Christopher Brandys, MD FRCS FACS | |
|
1404 River Pl, Suite 201, Braselton, GA 30517-5600 | |
| (770) 219-9200 | |
| (770) 219-9274 |
| Full Name | J Christopher Brandys |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 1404 River Pl, Braselton, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588618391 | NPI | - | NPPES |
| 386598893G | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 053639 (Georgia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| J Christopher Brandys, MD FRCS FACS 1404 River Pl, Suite 201, Braselton, GA 30517-5600 Ph: (770) 219-9200 | J Christopher Brandys, MD FRCS FACS 1404 River Pl, Suite 201, Braselton, GA 30517-5600 Ph: (770) 219-9200 |
News Archive
Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.
With a staff of 53 researchers of various nationalities, in a building of around 1,000 square metres, the Center for Nano Science and Technology is focused on technological innovation starting with basic research. In particular, the specific fields of application are photovoltaic conversion, biomimetic systems and plastic electronics.
Par Pharmaceutical Companies, Inc. today announced that its generic division, Par Pharmaceutical, has entered into an exclusive licensing agreement with Glenmark Generics Limited and Glenmark Generics Inc., USA to market ezetimibe 10 mg tablets, the generic version of Merck & Co. Inc.'s Zetia, in the U.S. Zetia is a cholesterol modifying agent with annual U.S. sales of approximately $1.4 billion, according to IMS Health data.
NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.
› Verified 7 days ago
Dr. Samer Othman Alharthi, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 1400 River Pl, Braselton, GA 30517 Phone: 770-848-8000 | |
Christopher William Soika, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1404 River Pl Ste 201, Braselton, GA 30517 Phone: 770-219-9200 | |
Lya Crichlow, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1404 River Pl Ste 201, Braselton, GA 30517 Phone: 770-219-9200 | |
Sumona Smith, Surgery Medicare: Accepting Medicare Assignments Practice Location: 1404 River Pl, Suite 201, Braselton, GA 30517 Phone: 770-219-4000 Fax: 770-219-4001 | |
Hasco William Craver Iii, D.O. Surgery Medicare: Not Enrolled in Medicare Practice Location: 494 Gold Crest Dr, Braselton, GA 30517 Phone: 706-654-3354 | |
James George Chambers Iv, M.D., PHD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1404 River Pl, Suite 201, Braselton, GA 30517 Phone: 770-219-9200 Fax: 770-219-9273 |